Free Trial

HLS Therapeutics Q4 2023 Earnings Report

HLS Therapeutics logo
C$3.99 +0.02 (+0.50%)
As of 01/17/2025 04:00 PM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.18
Consensus EPS
-C$0.13
Beat/Miss
Missed by -C$0.05
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$21.60 million
Expected Revenue
$21.83 million
Beat/Miss
Missed by -$230.00 thousand
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

HLS Therapeutics Earnings Headlines

Optimistic Buy Rating for HLS Therapeutics Despite Revenue Challenges
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS), a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat